sofosbuvir/velpatasvir/voxilaprevir
General
Genetic Implications: 
Pronunciation: 
soe-fos-bue-vir/vel-pat-as-vir/vox-i-la-pre-vir
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Vosevi
 
Ther. Class.
Pharm. Class.
NS5B inhibitors
NS5A inhibitors
protease inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Sofosbuvir/velpatasvir/voxilaprevir." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2025. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110523/all/sofosbuvir_velpatasvir_voxilaprevir. 
Vallerand AHA, Sanoski CAC,  . Sofosbuvir/velpatasvir/voxilaprevir. Davis's Drug Guide. F.A. Davis Company; 2025. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110523/all/sofosbuvir_velpatasvir_voxilaprevir. Accessed November 3, 2025.
Vallerand, A. H., Sanoski, C. A., & ,  (2025). Sofosbuvir/velpatasvir/voxilaprevir. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110523/all/sofosbuvir_velpatasvir_voxilaprevir
Vallerand AHA, Sanoski CAC,  . Sofosbuvir/velpatasvir/voxilaprevir [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2025. [cited 2025 November 03]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110523/all/sofosbuvir_velpatasvir_voxilaprevir.
* Article titles in AMA citation format should be in sentence-case
TY  -  ELEC
T1  -  sofosbuvir/velpatasvir/voxilaprevir
ID  -  110523
A1  -  Sanoski,Cynthia A,
AU  -  Vallerand,April Hazard,
AU  -  ,,
BT  -  Davis's Drug Guide
UR  -  https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110523/all/sofosbuvir_velpatasvir_voxilaprevir
PB  -  F.A. Davis Company
ET  -  19
DB  -  Medicine Central
DP  -  Unbound Medicine
ER  -  

Davis's Drug Guide

